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Background & aims: Melatonin may beneﬁt diabetic people with coronary heart disease (CHD) through
its beneﬁcial effects on biomarkers of oxidative stress and cardio-metabolic risk. This investigation
evaluated the effects of melatonin administration on metabolic status in diabetic patients with CHD.
Methods: This randomized, double-blind, placebo-controlled trial was conducted and involved 60 dia-
betic patients with CHD. Subjects were randomly allocated into two groups to receive either 10 mg
melatonin (2 melatonin capsules, 5 mg each) (n ¼ 30) or placebo (n ¼ 30) once a day for 12 weeks.
Results: Compared with the placebo, melatonin supplementation resulted in signiﬁcant increases in plasma
glutathione (GSH) (þ64.7 ± 105.7 vs. 11.1 ± 137.6 mmol/L, P ¼ 0.02) and nitric oxide (NO) (þ0.9 ± 4.7
vs. 3.3 ± 9.6 mmol/L, P ¼ 0.03), and signiﬁcant decreases in malondialdehyde (MDA) (0.2 ± 0.3
vs. þ0.1 ± 0.5 mmol/L, P ¼ 0.007), protein carbonyl (PCO) (0.12 ± 0.08 vs. þ0.03 ± 0.07 mmol/mg protein,
P < 0.001) and serum high sensitivity C-reactive protein (hs-CRP) levels (1463.3 ± 2153.8
vs.þ122.9 ± 1230.4 ng/mL, P¼ 0.001). In addition, takingmelatonin, comparedwith the placebo, signiﬁcantly
reduced fasting plasma glucose (29.4 ± 49.0 vs. 5.5 ± 32.4 mg/dL, P ¼ 0.03), serum insulin concentrations
(2.2 ± 4.1 vs. þ0.7 ± 4.2 mIU/mL, P ¼ 0.008), homeostasis model of assessment-estimated insulin resistance
(1.0± 2.2 vs.þ0.01± 1.6, P¼ 0.04), total-/HDL-cholesterol ratio (0.18± 0.38 vs.þ0.03± 0.35, P¼ 0.02) and
systolic (4.3±9.6 vs.þ1.0±7.5mmHg, P¼ 0.01) anddiastolic bloodpressure (2.8±7.3 vs.þ0.1±3.6mmHg,
P ¼ 0.04). Melatonin treatment also signiﬁcantly increased quantitative insulin sensitivity check index
(þ0.006 ± 0.01 vs. 0.004 ± 0.01, P ¼ 0.01) and serum HDL-cholesterol (þ2.6 ± 5.5 vs. 0.01 ± 4.4 mg/dL,
P ¼ 0.04). Supplementation with melatonin had no signiﬁcant effect on other metabolic parameters.
Conclusions: Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneﬁcial effects
on plasma GSH, NO, MDA, PCO, serum hs-CRP levels, glycemic control, HDL-cholesterol, total-/HDL-
cholesterol ratio, blood pressures and parameters of mental health. Registered under ClinicalTrials.gov
Identiﬁer no. http://www.irct.ir: IRCT2017051333941N1.
© 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) is a main risk factor for Coro-
nary heart disease (CHD) [1]. Multiple studies demonstrated CHD isent of Nutrition, Kashan Uni-
f Iran. Fax: þ98 31 55463377.
for Clinical Nutrition and Metabolresponsible for more than 80% of death in subjects with T2DM, and
unfortunately, the actual number of subjects with T2DM is esti-
mated to double by the year 2030, exhibiting an elevation in
mortality rate during the coming years [2]. Increased parameters of
oxidative stress and inﬂammation as well as rises in the risk of CHD,
T2DM and metabolic syndrome (MetS) are participated [3]. In
addition, insulin resistance, hyperglycemia and dyslipidemia in
people with T2DM may play in the development of atherosclerotic
disorders [4]. On the other hand, metabolic disorders in T2DM leadism. All rights reserved.
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which in turn play a major function in vascular events [5].
A few studies have showed that circulating melatonin levels are
altered in people with T2DM and CHD. For example, the nighttime
melatonin concentrations were changed in subjects with diabetes
and proliferative diabetic retinopathy [6]. Moreover, an indepen-
dent relationship between nocturnal levels of oxidized low-density
lipoprotein andmelatonin in peoplewithmyocardial infarctionwas
reported [7]. Some studies have demonstrated the beneﬁcial effects
of melatonin supplementation on biomarkers of oxidative stress
and inﬂammation, blood pressures, glycemic control and lipid
proﬁles in animal models and people with T2DM and MetS [8e10].
Dominguez-Rodriguez et al. [7] observed that melatonin adminis-
tration for 6 weeks in Zucker diabetic fatty (ZDF) rats ameliorated
the pro-inﬂammatory state and oxidative stress. Similarly, mela-
tonin supplementation (6 mg/day) for 40 days to obese women
signiﬁcantly improved inﬂammatory and oxidative stress factors
[11]. In addition, melatonin administration for 12 weeks improved
insulin sensitivity in old obese rats [12].
Given the antioxidant and anti-inﬂammatory effects of mela-
tonin, we hypothesized that melatonin might be beneﬁcial in dia-
betic people with CHD. The present study was, therefore,
performed to evaluate the effects of melatonin supplementation on
biomarkers of oxidative stress and cardio-metabolic risk in diabetic
patients with CHD.
2. Subjects and methods
2.1. Participants and ethics statements
This randomized, double-blind, placebo-controlled trial, regis-
tered in the Iranian registry of clinical trials (http://www.irct.ir:
IRCT2017051333941N1), was carried out at a cardiology clinic
afﬁliated to Kashan University of Medical Sciences (KUMS), Kashan,
Iran, between May 2017 and August 2017. Overweight people
(BMI  25 kg/m2) with T2DM, aged 50e85 years old with 2- and 3-
vessel CHD were included. Diagnosis of T2DM and CHD was con-
ducted based on the criteria of the American Diabetes Association
and American Heart Association, respectively. Those consuming
melatonin supplements within the last 3 months, having an acute
myocardial infarction and cardiac surgery within the past 3
months, and the night shift workers were not included in this
study. This study was done according to the principals of the
Declaration of Helsinki. Written informed consent was obtained
from all subjects prior to the intervention.
2.2. Study design
At ﬁrst, all participants were categorized according to age (<65
and 65 y), BMI (25e29.9 and 30 kg/m2), gender, the severity of
CHD (2-and 3-vessel disease), and the dosage and kind of medi-
cations. Then, participants were randomly allocated into two
groups to take either 10 mgmelatonin (2 melatonin capsules, 5 mg
each) (n ¼ 30) or placebo (n ¼ 30) once a day 1 h before bedtime
for 12 weeks. Melatonin and its placebo (parafﬁn) were produced
by NUTRALab Pharmaceutical Company (Scarborough, Canada)
and Barij Essence Pharmaceutical Company (Kashan, Iran),
respectively. Both melatonin supplements and placebo capsules
had similar packaging and people and investigators were unaware
of the content of the package until the end of study. Randomization
assignment was conducted using computer-generated random
numbers as blindness by a trained staff at the cardiology clinic.
Compliance with the intake of supplements and placebos was
determined by examining the capsule containers. In addition,
participants received a daily reminder message on their cellphones to take their supplements regularly. All participants
completed 3-d dietary records at weeks 1, 4, 8 and 12 of the trial.
Participants also monitored about their usual diet, the time of
melatonin assumption each day and their number of sleep hours.
To obtain nutrient intakes of participants according to 3-d food
records, we applied Nutritionist IV software (First Databank, San
Bruno, CA).
2.3. Assessment of anthropometric measures
Anthropometric measures (Seca, Hamburg, Germany) were
measured at baseline and after intervention. BMI was calculated as
weight in kg divided by height in meters squared.
2.4. Assessment of outcomes
Biomarkers of oxidative stress were considered as the primary
outcomes and other metabolic proﬁles, blood pressures and pa-
rameters of mental healthwere deﬁned as the secondary outcomes.
Ten milliliter fasting blood samples were collected at the beginning
and after the 12-week intervention at Kashan reference laboratory,
Kashan, Iran. Plasma total antioxidant capacity (TAC) concentra-
tions using the method of ferric reducing antioxidant power
developed by Benzie and Strain [13], total glutathione (GSH) using
the method of Beutler and Gelbart [14] and malondialdehyde
(MDA) concentrations by the thiobarbituric acid reactive sub-
stances spectrophotometric test were determined with coefﬁcient
of variations (CVs) lower than 5%, respectively. Plasma protein
carbonyl (PCO) levels were quantiﬁed using a spectrophotometric
method [15] with inter- and intra-assay CVs of lower than 5%.
Serum high-sensitivity C-reactive protein (hs-CRP) by commercial
ELISA kit (LDN, Nordhorn, Germany) and insulin levels by the use of
an ELISA kit (DiaMetra, Milano, Italy) with inter- and intra-assay
CVs of lower than 7%. The plasma nitric oxide (NO) levels were
determined using Griess method. The homeostasis model of
assessment-insulin resistance (HOMA-IR) and the quantitative in-
sulin sensitivity check index (QUICKI) were determined according
to the standard formula. Enzymatic kits (Pars Azmun, Tehran, Iran)
were applied to evaluate fasting plasma glucose (FPG) and lipid
proﬁles with inter- and intra-assay CVs less than 5%. Systolic (SBP)
and diastolic blood pressure (DBP) was determined via a sphyg-
momanometer (ALPK2, Zhejiang, China). Blood pressures were
quantiﬁed between 08:00 and 09:00 AM by the same investigator
each time.
2.5. Clinical assessment
Beck Depression Inventory (BDI) was assessed using a self-
compiled questionnaire [16]. Anxiety measured by Beck Anxiety
Inventory (BAI) that developed by Beck et al. [17].
2.6. Statistical methods and sample size
Type one (a) and type two errors (b) were deﬁned as 0.05, and
0.20 (power ¼ 80%), respectively. According to the previous trial
[11], we used 0.29 nmol/L as the SD and 0.23 nmol/L as the
change in mean (d) of MDA as a primary outcome. Based on the
formula, we needed 25 people in each group; after allowing for 5
dropouts in each group, the ﬁnal sample size was 30 persons in
each group.
To determine the normal distribution of variables, the Kolmo-
goroveSmirnov test was used. The intention-to-treat (ITT) analysis
was applied for all randomly allocated subjects. To detect differ-
ences in the general characteristics and dietary intakes between the
two groups, independent samples t-test was used. Pearson Chi-
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determine the effects of biochemical parameters, we used repeated
measures analysis of variance. P values less than 0.05 were
considered as signiﬁcant. All statistical analyses were performed by
the Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
3. Results
One subject in the supplemented group and 2 patients in the
placebo group dropped out for personal reasons. However, all 60
participants were included in the ﬁnal analysis based on the ITT
principle (Fig. 1). The compliance ranged between 90% and 100%
throughout the study in both groups.
Therewere no signiﬁcant differences between the two groups in
terms of mean age, height, baseline weight, baseline BMI, baseline
metabolic equivalents and mean changes in weight and BMI
throughout the trial (Table 1). The frequency of smoking, con-
sumption of antidiabetic and antilipidemic drugs, hypertension
rate, consumption of angiotensin converting enzymes inhibitors,
aldosterone receptor blockers drugs and blocker drugs (b-blocker
and calcium channel blocker) of study participants were not sta-
tistically different between the two groups.
We observed no signiﬁcant changes in macro- and micro-
nutrients throughout the intervention between the two groups
(Table 2).
Compared with the placebo, melatonin supplementation
resulted in signiﬁcant increases in plasma GSH (þ64.7 ± 105.7
vs. 11.1 ± 137.6 mmol/L, P ¼ 0.02) and NO (þ0.9 ± 4.7Randomized (n
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Fig. 1. Summary of patvs. 3.3 ± 9.6 mmol/L, P ¼ 0.03), and signiﬁcant reductions in MDA
(0.2 ± 0.3 vs. þ0.1 ± 0.5 mmol/L, P ¼ 0.007), PCO (0.12 ± 0.08
vs. þ0.03 ± 0.07 mmol/mg protein, P < 0.001) and serum hs-CRP
levels (1463.3 ± 2153.8 vs. þ122.9 ± 1230.4 ng/mL, P ¼ 0.001).
In addition, taking melatonin, compared with the placebo, signiﬁ-
cantly decreased FPG (29.4 ± 49.0 vs. 5.5 ± 32.4 mg/dL,
P ¼ 0.03), insulin concentrations (2.2 ± 4.1 vs. þ0.7 ± 4.2 mIU/mL,
P ¼ 0.008), HOMA-IR (1.0 ± 2.2 vs. þ0.01 ± 1.6, P ¼ 0.04), total-/
HDL-cholesterol ratio (0.18 ± 0.38 vs. þ0.03 ± 0.35, P ¼ 0.02), SBP
(4.3 ± 9.6 vs. þ1.0 ± 7.5 mmHg, P ¼ 0.01) and DBP (2.8 ± 7.3
vs. þ0.1 ± 3.6 mmHg, P ¼ 0.04), and signiﬁcantly increased QUICKI
(þ0.006 ± 0.01 vs. 0.004 ± 0.01, P ¼ 0.01) and serum HDL-
cholesterol (þ2.6 ± 5.5 vs. 0.01 ± 4.4 mg/dL, P ¼ 0.04). Addi-
tionally, melatonin supplementation signiﬁcantly improved BDI
(2.7 ± 1.8 vs. 0.7 ± 0.9, P < 0.001) and BAI (2.0 ± 3.4
vs. 0.4 ± 1.1, P ¼ 0.02) compared with the placebo. Supplemen-
tation with melatonin had no signiﬁcant effect on other metabolic
proﬁles compared with the placebo (Table 3).
4. Discussion
We found that melatonin supplementation after 12 weeks to
diabetic people with CHD had beneﬁcial effects on plasma GSH, NO,
MDA, PCO, serum hs-CRP levels, glycemic control, HDL-cholesterol,
total-/HDL-cholesterol ratio, blood pressures and parameters of
mental health. To our knowledge, this is the ﬁrst report of mela-
tonin intake on biomarkers of oxidative stress and inﬂammation,
glycemic control, lipid proﬁles, blood pressures and parameters of
mental health among diabetic people with CHD.=60) 
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Table 1
General characteristics of study participants at baseline study.
Placebo group
(n ¼ 30)
Melatonin group
(n ¼ 30)
Pa
Age (y) 65.3 ± 10.1 67.7 ± 11.4 0.40
Gender
Female 17 (56.7) 16 (53.3) 0.79b
Male 13 (43.3) 14 (46.7)
Height (m) 161.3 ± 9.3 157.1 ± 12.6 0.14
Weight at study baseline (kg) 77.1 ± 11.2 75.4 ± 15.2 0.62
Weight at end-of-trial (kg) 77.2 ± 11.8 75.8 ± 15.9 0.71
Body weight change (kg) 0.1 ± 2.5 0.5 ± 1.8 0.50
BMI at study baseline (kg/m2) 29.7 ± 4.4 30.4 ± 4.3 0.53
BMI at end-of-trial (kg/m2) 29.7 ± 4.4 30.6 ± 4.4 0.46
BMI change (kg/m2) 0.01 ± 1.0 0.2 ± 0.7 0.49
MET-h/d at study baseline 25.9 ± 2.1 26.1 ± 2.4 0.68
MET-h/d at end-of-trial 25.7 ± 2.1 26.1 ± 2.4 0.45
MET-h/d change 0.2 ± 0.7 0.004 ± 0.7 0.30
The severity of CHD
2-vessel disease 12 (40) 11 (36.7) 1.00b
3-vessel disease 18 (60) 19 (63.3)
Smoking (%) 2 (6.7) 2 (6.7) 1.00b
Aspirin 80 mg (%) 30 (100) 30 (100) 1.00b
Statin (%) 30 (100) 30 (100) 1.00b
Insulin therapy (%) 10 (33.3) 9 (30.0) 1.00b
Antidiabetic drugs (%)
Monotherapy 17 (70.8) 18 (72.0)
Combination therapy 7 (29.2) 7 (28.0) 1.00b
Hypertension (%) 22 (73.3) 22 (73.3) 1.00b
ACEI/ARB drugs (%) 30 (100) 30 (100) 1.00b
Blocker drugs (%)
b-blocker 28 (93.3) 27 (90.0)
Calcium channel blocker 2 (6.7) 3 (10.0) 1.00b
Data are means ± SDs.
ACEI, angiotensin converting enzymes inhibitors; ARB, aldosterone receptor
blockers; CHD, coronary heart disease; METs, metabolic equivalents.
a Obtained from independent samples t-test.
b Obtained from Fisher's exact test.
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cebo, taking melatonin for 12 weeks by diabetic people with CHD
signiﬁcantly increased plasma GSH and NO, and signiﬁcantly
decreased plasma MDA, PCO and serum hs-CRP levels, but plasmaTable 2
Dietary intakes of type 2 diabetic patients with coronary heart disease at study
baseline and throughout the study.a
Placebo group
(n ¼ 30)
Melatonin group
(n ¼ 30)
Pb
Energy (kcal/d) 2349 ± 188 2360 ± 247 0.85
Carbohydrates (g/d) 328.3 ± 31.5 321.1 ± 63.5 0.58
Protein (g/d) 81.9 ± 12.7 88.2 ± 16.8 0.10
Fat (g/d) 82.8 ± 10.6 83.9 ± 14.5 0.74
SFA (g/d) 24.7 ± 3.9 26.6 ± 5.2 0.12
PUFA (g/d) 25.3 ± 5.8 26.1 ± 6.3 0.60
MUFA (g/d) 23.2 ± 6.3 23.7 ± 6.1 0.74
Cholesterol (mg/d) 221.7 ± 127.0 214.2 ± 102.2 0.80
TDF (g/d) 20.5 ± 4.3 18.8 ± 4.6 0.15
Calcium (mg/d) 1149.8 ± 181.8 1167.7 ± 160.8 0.68
Zinc (mg/d) 10.1 ± 2.1 10.9 ± 2.3 0.14
Magnesium (mg/d) 287.9 ± 60.6 284.5 ± 55.3 0.81
Manganese (mg/d) 2.5 ± 0.7 2.3 ± 0.9 0.47
Selenium (mg/d) 56.3 ± 6.3 55.2 ± 6.0 0.53
Vitamin D (mg/d) 2.8 ± 0.7 2.8 ± 0.8 0.91
Vitamin C (mg/d) 74.0 ± 12.5 72.9 ± 13.6 0.74
Vitamin B2 (mg/d) 1.8 ± 0.3 1.7 ± 0.2 0.72
Vitamin B6 (mg/d) 1.6 ± 0.7 1.4 ± 0.3 0.15
Folate (mg/d) 297.8 ± 79.1 279.8 ± 95.5 0.43
Vitamin B12 (mg/d) 3.9 ± 1.0 4.2 ± 1.0 0.17
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs,
saturated fatty acids; TDF, total dietary ﬁber.
a Values are means ± SDs.
b Obtained from independent samples t-test.TAC levels did not inﬂuence by melatonin supplementation.
Earlier, observational and interventional studies have docu-
mented that melatonin supplementation has anti-inﬂammatory
effects and antioxidant actions [18], but the ﬁndings have not
always consistent. Dominguez-Rodriguez et al. [7] demonstrated
that melatonin supplementation for 6 weeks in ZDF rats
improved the pro-inﬂammatory state and reduced oxidative
stress. In addition, melatonin supplementation (6 mg/day) for 40
days to obese women signiﬁcantly improved biomarkers oxida-
tive stress and inﬂammatory factors [11]. Melatonin supplemen-
tation at a dosage of 5 mg/day for 8 weeks among people with
metabolic syndrome also reduced MDA and increased catalase
activity [10]. Moreover, taking melatonin at a dosage of 5 mg/day
for 30 days to patients with T2DM resulted in a signiﬁcant in-
crease in superoxide dismutase activity and a signiﬁcant reduc-
tion in MDA concentrations [19]. Increased lipid peroxidation
products; especially MDA is possibly correlated with many dis-
eases such as cancer, cardiovascular disease (CVD) and diabetes
mellitus [20]. Moreover, lipid peroxidation products have an
important role in the pathogenesis of diabetes [20]. Previous
studies demonstrated that the endothelium of patients with
diabetes do not produce sufﬁcient amount of NO [21]. Therefore,
decreasing oxidative stress and inﬂammation with melatonin
may decrease diabetes and CVD events. Melatonin inhibits
oxidation reactions catalyzed by scavenges reactive oxygen spe-
cies, thereby decreasing lipid peroxidation [22]. Likewise, taking
melatonin may reduce oxidative stress through regulating the
activities of antioxidative enzymes [23] and stimulating gluta-
thione synthesis via promoting glucose-6-phosphate dehydroge-
nase activity [24].
We found that 12-week melatonin supplementation to diabetic
people with CHD was associated with signiﬁcant reductions in FPG,
serum insulin, HOMA-IR, and a signiﬁcant rise in QUICKI compared
with the placebo. In previous two studies by Peschke et al. [8,9] a
signiﬁcant reduction in insulin values and an elevated expression of
melatonin receptors after enteral intake was reported in both
normal Wistar and type 2 diabetic Goto-Kakizaki rats. In addition,
melatonin supplementation in combination with exercise signiﬁ-
cantly improved insulin resistance, hypertension, and inﬂamma-
tory cytokines via up-regulation of glucose transporter type 4,
peroxisome proliferator-activated receptor gamma coactivator 1a
and mitochondrial biogenesis in T2DM rats [25]. Melatonin
administration due to its glucose-lowering effect might be effective
to decrease diabetic complications. The inhibitory effects of mela-
tonin intake on insulin metabolism may be explained via two G-
protein-coupled receptors, MT1 (cAMP signaling pathway) and
MT2 (cGMP signaling pathway) [26].
The current study demonstrated that compared with the pla-
cebo, the 12-week melatonin supplementation to diabetic patients
with CHD resulted in a signiﬁcant reduction in HDL-cholesterol and
signiﬁcant drop in total-/HDL-cholesterol ratio and blood pressures,
but serum triglycerides, VLDL-, total- and LDL-cholesterol levels did
not affect by melatonin supplementation. Agil et al. [27] found that
melatonin intake in ZDF rats signiﬁcantly increased HDL-
cholesterol, and decreased LDL-cholesterol; but it had no effect
on total cholesterol levels. However, supplementation with 6 mg/
day of melatonin for 2 weeks increased VLDL-cholesterol, but did
not inﬂuence LDL- and HDL-cholesterol concentrations in post-
menopausal women [28]. Dyslipidemia in diabetic and CVD people
is characterized by moderately increased triglycerides and reduced
HDL-cholesterol concentrations; these changes contribute to
atherosclerotic cardiovascular diseases [29]. Melatonin may in-
crease HDL-cholesterol through augmented cholesterol esteriﬁca-
tion mediated by higher lecithin-cholesterol acyltransferase
activity [30].
Table 3
Biomarkers of oxidative stress and cardio-metabolic risk at baseline and after the 12-week intervention in type 2 diabetic patients with coronary heart disease.
Placebo group (n ¼ 30) Melatonin group (n ¼ 30) Pa
Baseline End-of-trial Change Baseline End-of-trial Change
TAC (mmol/L) 876.4 ± 190.9 884.0 ± 363.4 7.6 ± 271.6 734.8 ± 68.4 748.8 ± 93.7 14.0 ± 63.9 0.90
GSH (mmol/L) 546.2 ± 148.4 535.1 ± 181.1 11.1 ± 137.6 604.0 ± 79.3 668.7 ± 103.5 64.7 ± 105.7 0.02
MDA (mmol/L) 2.9 ± 0.8 3.0 ± 0.7 0.1 ± 0.5 2.6 ± 0.2 2.4 ± 0.2 0.2 ± 0.3 0.007
PCO (nmol/mg protein) 2.17 ± 0.15 2.20 ± 0.16 0.03 ± 0.07 2.15 ± 0.17 2.03 ± 0.17 0.12 ± 0.08 <0.001
hs-CRP (ng/mL) 3619.2 ± 3416.2 3742.2 ± 3406.9 122.9 ± 1230.4 4040.0 ± 2318.4 2576.7 ± 1763.9 1463.3 ± 2153.8 0.001
NO (mmol/L) 41.9 ± 5.2 38.6 ± 8.1 3.3 ± 9.6 46.1 ± 3.8 47.0 ± 5.0 0.9 ± 4.7 0.03
FPG (mg/dL) 156.5 ± 60.1 151.0 ± 55.0 5.5 ± 32.4 170.9 ± 60.3 141.5 ± 49.2 29.4 ± 49.0 0.03
Insulin (mIU/mL) 12.2 ± 7.3 12.9 ± 7.2 0.7 ± 4.2 13.7 ± 6.5 11.5 ± 4.8 2.2 ± 4.1 0.008
HOMA-IR 4.8 ± 3.7 4.8 ± 3.4 0.01 ± 1.6 6.0 ± 3.9 5.0 ± 2.9 1.0 ± 2.2 0.04
QUICKI 0.31 ± 0.03 0.31 ± 0.02 0.004 ± 0.01 0.30 ± 0.02 0.31 ± 0.02 0.006 ± 0.01 0.01
Triglycerides (mg/dL) 145.7 ± 53.1 143.8 ± 46.9 1.9 ± 31.6 142.0 ± 73.8 140.4 ± 70.1 1.6 ± 35.6 0.97
VLDL-cholesterol (mg/dL) 29.1 ± 10.6 28.8 ± 9.4 0.3 ± 6.3 28.4 ± 14.8 28.1 ± 14.0 0.3 ± 7.1 0.97
Total cholesterol (mg/dL) 141.4 ± 19.5 142.6 ± 19.3 1.2 ± 15.4 129.7 ± 24.1 129.7 ± 22.4 0.1 ± 5.4 0.70
LDL-cholesterol (mg/dL) 66.4 ± 18.0 68.0 ± 17.5 1.6 ± 15.5 59.8 ± 24.7 57.5 ± 21.2 2.2 ± 9.6 0.25
HDL-cholesterol (mg/dL) 45.9 ± 8.1 45.9 ± 8.7 0.01 ± 4.4 41.5 ± 7.3 44.2 ± 7.9 2.6 ± 5.5 0.04
Total-/HDL-cholesterol ratio 3.16 ± 0.63 3.19 ± 0.66 0.03 ± 0.35 3.18 ± 0.61 2.99 ± 0.59 0.18 ± 0.38 0.02
SBP (mmHg) 129.9 ± 11.1 130.9 ± 11.8 1.0 ± 7.5 134.0 ± 11.5 129.7 ± 7.5 4.3 ± 9.6 0.01
DBP (mmHg) 80.2 ± 7.0 80.3 ± 6.1 0.1 ± 3.6 78.5 ± 6.7 75.7 ± 6.0 2.8 ± 7.3 0.04
BDI score 21.8 ± 3.8 21.1 ± 3.9 0.7 ± 0.9 21.1 ± 4.4 18.3 ± 4.3 2.7 ± 1.8 <0.001
BAI score 15.3 ± 4.8 14.9 ± 5.2 0.4 ± 1.1 14.8 ± 5.4 12.8 ± 4.1 2.0 ± 3.4 0.02
All values are means ± SDs.
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model
of assessment-estimated insulin resistance; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; PCO, protein carbonyl; QUICKI, quantitative
insulin sensitivity check index; SBP, systolic blood pressure; TAC, total antioxidant capacity.
a P values represent the time  group interaction (computed by analysis of the one-way repeated measures ANOVA).
F. Raygan et al. / Clinical Nutrition 38 (2019) 191e196 195The current study had some limitations. We did not evaluate the
effects of melatonin supplementation on serum and/or urinary
melatonin. In addition, this study was adequately powered for
examining the primary objective.
Overall, 10 mg/day of melatonin supplementation after 12
weeks among diabetic people with CHD had beneﬁcial effects on
plasma GSH, NO, MDA, PCO, serum hs-CRP levels, glycemic control,
HDL-cholesterol, total-/HDL-cholesterol ratio, blood pressures and
parameters of mental health. A longer treatment or a supplemen-
tation with a higher dose of melatonin may affect TAC or other
cardio-metabolic markers.Authors' contributions
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